Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 1;13:953721. doi: 10.3389/fimmu.2022.953721

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Xu, Anwaier, Liu, Wei, Su, Tian, Xia, Qu, Zhao, Zhang and Ye

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Clinical value of MTAP/CDKN2A ^MUT in sarcomatoid and the prognosis of 574 patients with renal cell carcinoma (RCC) from the discovery set of the Fudan University Shanghai Cancer Center (FUSCC) cohort. (A) Genomic alteration frequency of MTAP and CDKN2A in 574 Chinese patients with RCC from the FUSCC cohort; 3,563 RCC samples from 17 independent cohorts were integrated (Western cohort), and 1,170 Chinese patients with RCC were included from the 3D medicine cohort with panel sequencing data. (B) The proportion of sarcomatoid pathological features in 574 patients with RCC from the FUSCC cohort in different mutation groups. (C) The representative images of sarcomatoid pathological features in MTAP/CDKN2A^MUT samples. (D) Classified by the MTAP/CDKN2A^MUT , progression-free survival (PFS) and overall survival (OS) of 574 RCC patients from the FUSCC cohort using Kaplan–Meier curve analysis. ****, P<0.0001.